Application of mozavaptan and elthrenone compound composition in preparation of product for treating or preventing motion sickness

The combined use of mozavaptane and isalidomide has solved the problems of poor efficacy and large side effects of existing anti-motion sickness drugs, and provides an effective prevention and treatment solution before or during motion sickness, reducing side effects and making it suitable for operations in special environments such as navigation, aviation, and aerospace.

CN118924764AInactive Publication Date: 2024-11-12NANTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411049435.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing anti-motion sickness drugs are ineffective in preventing and treating motion sickness and have significant side effects, especially central nervous system depression and blurred vision, which affect work in special environments and their effectiveness weakens after motion sickness occurs.

Method used

A combination of mozavaptane and isalidomide, used as an antidiuretic hormone receptor V2R antagonist and a third-generation mineralocorticoid receptor antagonist, is used in combination at half the original effective dose to exert a synergistic effect. It is prepared as an injection, infusion or oral dosage form for the prevention or treatment of motion sickness.

Benefits of technology

It achieves effective prevention and treatment of motion sickness before or during its occurrence, reduces or alleviates drug side effects, significantly inhibits the manifestation of motion sickness, and is suitable for operations in special environments such as navigation, aviation, and aerospace.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924764A_ABST
    Figure CN118924764A_ABST
Patent Text Reader

Abstract

The invention provides an application of a mozavaptan and elsandstone compound composition in preparation of a product for treating or preventing motion sickness, relates to preparation of biological medicines, and is technically characterized in that the application of the mozavaptan and elsandstone compound composition in preparation of the product for treating or preventing motion sickness is provided. The product has an anti-motion sickness effect when or before motion sickness occurs. The mozavaptan and elthrenone compound composition can avoid the problems of central side effects of the existing anti-motion sickness medicines and poor treatment effect of the existing medicines after motion sickness. Therefore, the mozavaptan and elthrenone compound composition can relieve the motion sickness condition, relieve the pain of a patient, and ensure that people can travel pleasantly and comfortably and work smoothly in a special environment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of biopharmaceutical technology, and specifically relates to the use of a compound composition of mozavaptan and esalidon in the preparation of a product for treating or preventing motion sickness. Background Art

[0002] When people are riding in vehicles, ships, airplanes, or doing navigation, aviation, aerospace, or in virtual reality, they are exposed to abnormal vestibular stimulation or / and abnormal visual stimulation. Many people will experience motion sickness (or motion sickness), which is mainly manifested by pale complexion, cold sweat, salivation, indifference, abdominal discomfort, dizziness, nausea, vomiting, etc. It is also called motion sickness, seasickness, navigation motion sickness, airsickness, aviation motion sickness, aerospace motion sickness, simulator sickness, etc. Literature shows that almost all crew members will get seasick when sailing in bad sea conditions; during aerospace operations, the incidence of motion sickness can still reach 60%-80% despite simulated training on the ground. Although motion sickness will gradually ease after leaving the sports environment, it obviously affects people's normal travel and operations in special environments such as aviation, aerospace, and navigation. At present, the detailed pathogenesis of motion sickness is still not very clear, and there is still a lack of efficient and side-effect-free drugs for prevention and treatment. Existing anti-motion sickness drugs include antihistamines, anticholinergics, sympathomimetics, calcium antagonists, gastrokinetics, traditional Chinese medicines such as salvia miltiorrhiza, gastrodia elata, ginger or compound preparations, etc.

[0003] At present, the most commonly used drug for preventing and treating motion sickness is the antihistamine dimenhydrinate, and the most effective single drug is the anticholinergic scopolamine, but the effective sites of these drugs are not very clear, and the side effects are also large, especially the side effects such as central inhibition, blurred vision, memory impairment, etc., which affect people's operations under various special environmental conditions such as navigation, aviation, and aerospace. In addition, these drugs are mostly used before taking a vehicle. As a preventive drug for motion sickness, they are effective, but if motion sickness has already occurred, their effects are significantly weakened. Therefore, it is necessary to research and develop new anti-motion sickness drugs with good effects, strong specificity, no obvious toxic and side effects, especially no central inhibition side effects, especially drugs with obvious therapeutic effects. Summary of the invention

[0004] The present application provides the use of a compound composition of mozavaptan and esalidon in the preparation of a product for treating or preventing motion sickness, so as to solve the above-mentioned technical problems.

[0005] In order to solve the above technical problems, a technical solution adopted in this application is:

[0006] Application of a compound composition of mozavaptan and esalidon in preparing a product for treating or preventing motion sickness.

[0007] Preferably, the compound composition comprises mozavaptan and isalidone.

[0008] Preferably, the product is used when motion sickness occurs or before it occurs to produce an anti-motion sickness effect.

[0009] Preferably, the product is in the form of an injection, an infusion or an oral dosage form.

[0010] The present application provides a method for verifying that a compound composition of mozavaptan and isalidone inhibits motion sickness manifestations, comprising the following steps:

[0011] S1. Obtain the drinking amount and swimming trajectory of 0.15% sodium saccharin solution of normal guinea pigs;

[0012] S2. Obtain the drinking amount of 0.15% saccharin sodium solution of guinea pigs with motion sickness, the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with half the normal dose of mozavaptan, the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with half the normal dose of isalidone, and the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with a compound composition of half the normal dose of mozavaptan and half the normal dose of isalidone, and compare it with the drinking amount of 0.15% saccharin sodium solution of normal guinea pigs;

[0013] S3. Obtain the swimming trajectory of guinea pigs with motion sickness, the swimming trajectory of guinea pigs gavaged with half the normal dose of mozavaptan, the swimming trajectory of guinea pigs gavaged with half the normal dose of isalidone, and the swimming trajectory of guinea pigs gavaged with a combination of half the normal dose of mozavaptan and half the normal dose of isalidone, and compare them with the swimming trajectory of normal guinea pigs.

[0014] The beneficial effects of the present application are as follows: Mozavaptan in the present application is an antagonist of the antidiuretic hormone receptor V2R, which has a certain preventive and therapeutic effect on motion sickness. At the same time, esalidonate, a third-generation mineralocorticoid receptor antagonist, also has a certain preventive and therapeutic effect on motion sickness. The two are formulated into a compound and used in combination, each using half of the original effective dose, to exert a synergistic effect from different links, to achieve a good effect of preventing and treating motion sickness, and at the same time reduce or alleviate the side effects of the original drugs. It can be used when motion sickness has already occurred, or it can be used before taking a means of transportation. When motion sickness occurs, because the patient has nausea and vomiting, which affects the administration, it can be used through the intravenous route. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 is a graph showing changes in the amount of saccharin sodium solution consumed by guinea pigs in each experimental group of Example 1;

[0016] Figure 2 It is a statistical diagram of the curvature of the swimming trajectory of guinea pigs in each experimental group of Example 2. DETAILED DESCRIPTION

[0017] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention is further described in detail below in conjunction with specific embodiments.

[0018] In the following description, many specific details are set forth to facilitate a full understanding of the present invention. However, the present invention may also be implemented in other ways than those described herein. Therefore, the present invention is not limited to the specific embodiments of the following disclosure.

[0019] Use of a mozavaptan and ixalidone compound composition in preparing a product for treating or preventing motion sickness. The product comprises a mozavaptan and ixalidone compound composition. The product is used when or before motion sickness occurs to produce an anti-motion sickness effect. The product is in the form of an injection, an infusion or an oral dosage form.

[0020] The present application also provides a method for verifying that the mozavaptan and isalidone compound composition inhibits motion sickness manifestations, comprising the following steps:

[0021] S1. Obtain the drinking amount and swimming trajectory of 0.15% sodium saccharin solution of normal guinea pigs;

[0022] S2. Obtain the drinking amount of 0.15% saccharin sodium solution of guinea pigs with motion sickness, the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with half the normal dose of mozavaptan, the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with half the normal dose of isalidone, and the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with a compound composition of half the normal dose of mozavaptan and half the normal dose of isalidone, and compare it with the drinking amount of 0.15% saccharin sodium solution of normal guinea pigs;

[0023] S3. Obtain the swimming trajectory of guinea pigs with motion sickness, the swimming trajectory of guinea pigs gavaged with half the normal dose of mozavaptan, the swimming trajectory of guinea pigs gavaged with half the normal dose of isalidone, and the swimming trajectory of guinea pigs gavaged with a combination of half the normal dose of mozavaptan and half the normal dose of isalidone, and compare them with the swimming trajectory of normal guinea pigs.

[0024] Studies have shown that rotational stimulation can effectively induce motion sickness in guinea pigs. Guinea pigs are a type of rodent. Since rodents do not have a vomiting reflex, they will not vomit, but they will show conditioned taste aversion and abnormal movement trajectories. The former is used to reflect the nausea and vomiting of humans, and the latter is used to reflect the vestibular dysfunction of vertigo. Therefore, the present application uses rotational stimulation to induce motion sickness in guinea pigs, and uses the guinea pigs' aversion to 0.15% sodium saccharin solution and abnormal swimming trajectories as indicators, and observes that the mozavaptan and esalidon compound composition has a significant anti-motion sickness effect.

[0025] Example 1: Inhibitory effect of the compound composition of mozavaptan and esalidon on conditioned taste aversion behavior induced by rotary stimulation in guinea pigs

[0026] Mozavaptan hydrochloride used in the experiment was purchased from Guangzhou Kafen Biotechnology Co., Ltd., esaxerenone was purchased from Shanghai Farmer Biotechnology Co., Ltd., and saccharin sodium was produced by Tianjin Northern Food Co., Ltd. The experimental animals were ordinary guinea pigs, female, 2-3 months old, weighing 280-350g, purchased from the Experimental Animal Center of Nantong University. Guinea pigs were kept in plastic cages, free to move and eat, and fed with appropriate amounts of cabbage to supplement vitamins. The breeding environment was a 12h-12h light-dark cycle per day, a temperature of 22±2℃, and a relative humidity of 40%-70%, and the adaptive breeding was carried out for 3 days.

[0027] Control group (Con.): Guinea pigs were gavaged with an equal amount of physiological saline containing 0.5% sodium carboxymethyl cellulose, and the intake of 0.15% sodium saccharin solution by normal guinea pigs was continuously monitored two days before and two days after gavage, and the change in intake was calculated, i.e.: the percentage change in the intake of sodium saccharin solution = (the average intake of sodium saccharin solution 2 days after administration - the average intake 2 days before administration) / the average intake 2 days before administration.

[0028] Rotational stimulation group (Veh.): Guinea pigs were stimulated with a dual-axis compound rotational pattern to induce motion sickness, which was determined by measuring the reduction in the guinea pigs' intake of a pre-familiar 0.15% sodium saccharin solution (i.e., conditioned taste aversion behavior). The guinea pigs were placed in a rotational stimulation device and slowly rotated clockwise around the vertical axis at a constant speed (30° / s), and then rotated around the horizontal axis at a variable speed, first at 16° / s 2 The angular acceleration accelerates, rotating clockwise, and immediately after the angular velocity reaches the maximum value of 120° / s, it decreases to -48° / s 2 The angular acceleration of the guinea pig was decelerated until it stopped, with 10 seconds as one cycle. Subsequently, the guinea pig was rotated in the same counterclockwise direction for 10 seconds, and the stimulation was repeated for 120 minutes to induce motion sickness in the guinea pig. Immediately after the stimulation, the guinea pig was gavaged with an equal amount of saline containing 0.5% sodium carboxymethyl cellulose. The intake of 0.15% sodium saccharin solution by the guinea pig was continuously monitored two days before and after the rotation stimulation, and the changes in intake were calculated.

[0029] Mozavaptan gavage group (Moz.): firstly, the above-mentioned rotation stimulation was carried out, and immediately after the stimulation, half of the normal dose of mozavaptan (5.5 mg / kg) was gavaged to the guinea pigs, and the intake of 0.15% saccharin sodium solution by normal guinea pigs was continuously monitored two days before and two days after the mozavaptan gavage, and the changes in intake were calculated to observe the effect of mozavaptan alone.

[0030] Isalidone gavage group (Esa.): firstly, the above-mentioned rotation stimulation was carried out, and immediately after the stimulation, half of the normal dose of isalidone (0.5 mg / kg) was gavaged to the guinea pigs, and the intake of 0.15% sodium saccharin solution of normal guinea pigs was continuously monitored two days before and two days after the gavage of isalidone, and the changes in the intake were calculated to observe the effect of simple isalidone.

[0031] Group of compound composition gavage after rotation stimulation (Moz.+Esa.): First, the above-mentioned rotation stimulation was carried out under the same conditions. Immediately after the stimulation, the guinea pigs were gavaged with a compound composition of mozavaptan (5.5 mg / kg) at half the normal dose and esalidon (0.5 mg / kg) at half the normal dose. The changes in the intake of 0.15% saccharin sodium solution were observed and compared with the performance of the control group and the rotation stimulation group to determine the anti-motion sickness effect of the compound composition of mozavaptan and esalidon. The results of each experimental group were statistically processed by variance analysis, and the Duncan test was used for pairwise comparison.

[0032] See also Figure 1 Compared with the control group (Con.), the amount of saccharin sodium solution consumed by the guinea pigs in the rotation stimulation group (Veh.) after rotation was significantly less than that before rotation (P<0.01), indicating that the rotation stimulation caused the guinea pigs to develop a conditioned taste aversion behavior of drinking saccharin sodium solution, that is, motion sickness. Guinea pigs that were gavaged with mozavaptan (5.5 mg / kg, Moz.) or esalidon (0.5 mg / kg, Esa.) alone after rotation stimulation showed a decrease in the average amount of saccharin sodium solution consumed two days after rotation, but there was no significant difference compared with the simple rotation stimulation group (Veh.) (P>0.05), indicating that the inhibitory effect of half the normal dose of mozavaptan or esalidon on motion sickness was not obvious. However, after the combined use of half-dose mozavaptan and esalidon, the conditioned taste aversion behavior of guinea pigs induced by rotational stimulation was significantly inhibited (P<0.05, Moz.+Esa.), and the drinking amount of sodium saccharin solution returned to a level close to that of the control group, indicating that the combination of mozavaptan and esalidon has a significant anti-motion sickness effect.

[0033] Example 2: Inhibitory effect of the compound composition of mozavaptan and esalidon on the vestibular dysfunction induced by rotational stimulation in guinea pigs

[0034] Control group (Con.): Adaptive swimming training was performed on guinea pigs using the Morris water maze apparatus at a fixed time every day. Warm water was placed in a pool with a diameter of 1.8 m to ensure that the guinea pigs could not stand in the water. The platform in the water was removed and the guinea pig was gently placed in the center of the pool facing the pool wall. The swimming path of the guinea pig from the center to the pool wall was filmed with a camera system, and its movement trajectory was recorded and analyzed using ANY-maze software (Stoeling, USA). Each guinea pig repeated the training 5 times a day for 5 consecutive days. The swimming path of each guinea pig was observed and recorded. When its swimming trajectory was stable, the swimming trajectory was close to a straight line as the standard, and then the experiment was officially carried out. On the second day after the adaptive training, the guinea pigs were gavaged with an equal amount of physiological saline containing 0.5% sodium carboxymethyl cellulose. After 1 hour, the swimming trajectory of the guinea pig in a normal state was tested and recorded 5 times. The curvature of the guinea pig's swimming trajectory was calculated using the open source software Image J to obtain the average curvature of the swimming trajectory.

[0035] Rotation stimulation group (Rot.): The trained guinea pigs were subjected to 2 hours of rotation stimulation, and the stimulation parameters were the same as those of the conditioned taste aversion behavior induction experiment. Immediately after the stimulation, the guinea pigs were gavaged with an equal amount of physiological saline containing 0.5% sodium carboxymethylcellulose, and the swimming tracks of the guinea pigs were measured and recorded 5 times after 1 hour.

[0036] Mozavaptan gavage group (Moz.): firstly, the above-mentioned rotation stimulation was carried out. Immediately after the stimulation, half the normal dose of mozavaptan (5.5 mg / kg) was gavaged to the guinea pigs. After 1 hour, the swimming trajectory of the guinea pigs was measured and recorded 5 times to observe the effect of mozavaptan alone.

[0037] Isalidone gavage group (Esa.): First, the above-mentioned rotation stimulation was carried out. Immediately after the stimulation, the guinea pigs were gavaged with half the normal dose of isalidone (0.5 mg / kg). After 1 hour, the swimming trajectory of the guinea pigs was measured and recorded 5 times to observe the effect of simple isalidone.

[0038] The compound composition gavage group after rotation stimulation (Moz.+Esa.): The rotation stimulation under the same conditions as above was first performed, and immediately after the stimulation, the guinea pigs were gavaged with a compound composition of half the normal dose of mozavaptan (5.5 mg / kg) and half the normal dose of esalidon (0.5 mg / kg). After 1 hour, the swimming trajectory of the guinea pigs was measured and recorded 5 times, and compared with the performance of the control group and the rotation stimulation group to determine the anti-motion sickness effect of the compound composition of mozavaptan and esalidon. The results of each experimental group were statistically processed by variance analysis, and the Duncan test was used for pairwise comparison.

[0039] See also Figure 2Compared with the control group (Con.), the swimming path of the guinea pigs in the rotation stimulation group (Veh.) was curved after rotation, and the curvature of the swimming track increased significantly (P<0.01), indicating vestibular dysfunction. After rotation stimulation, the curvature of the swimming track of guinea pigs that were gavaged with mozavaptan (5.5mg / kg, Moz.) or esalione (0.5mg / kg, Esa.) decreased, but it was not significantly different from the simple rotation stimulation group (Veh.) (P>0.05), indicating that the normal half-dose of mozavaptan or esalione had no obvious inhibitory effect on motion sickness. However, after the combined use of half-dose mozavaptan and esalione, the increase in the curvature of the swimming track induced by rotation stimulation was significantly inhibited (P<0.01, Moz.+Esa.), indicating that the combination of mozavaptan and esalione inhibited the vestibular dysfunction of guinea pigs induced by rotation stimulation, that is, inhibited motion sickness.

[0040] The mozavaptan of the present application is an antagonist of the antidiuretic hormone receptor V2R, and it is found that it has a certain preventive and therapeutic effect on motion sickness. At the same time, esalidonate, a third-generation mineralocorticoid receptor antagonist, also has a certain preventive and therapeutic effect on motion sickness. Therefore, the two are formulated into a compound and used in combination, each using half of the original effective dose, and exerting a synergistic effect from different links to achieve a good effect of preventing and treating motion sickness, while reducing or alleviating the side effects of the original drugs. It can be used when motion sickness has already occurred, or it can be used before taking a means of transportation. When motion sickness occurs, because the patient has nausea and vomiting, it affects the taking of the drug, and it can be used by intramuscular injection or intravenous route.

[0041] The above description is only an embodiment of the present application and does not limit the patent scope of the present application. Any equivalent structure or equivalent process transformation made using the contents of the present application specification and drawings, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present application.

Claims

1. Use of a compound composition of mozavaptan and esalidon in the preparation of a product for treating or preventing motion sickness.

2. A product for treating or preventing motion sickness, characterized in that: It comprises a compound composition of mozavaptan and esalidon.

3. A product for treating or preventing motion sickness according to claim 2, characterized in that: The product produces an anti-motion sickness effect when used when or before motion sickness occurs.

4. A product for treating or preventing motion sickness according to claim 2, characterized in that: The product is in the form of an injection, an infusion or an oral dosage form.

5. A method for verifying that a mozavaptan and isalidone compound composition inhibits motion sickness symptoms, characterized in that: The following steps are involved: S1. Obtain the drinking amount and swimming trajectory of 0.15% sodium saccharin solution of normal guinea pigs; S2. Obtain the drinking amount of 0.15% saccharin sodium solution of guinea pigs with motion sickness, the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with half the normal dose of mozavaptan, the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with half the normal dose of isalidone, and the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with a compound composition of half the normal dose of mozavaptan and half the normal dose of isalidone, and compare it with the drinking amount of 0.15% saccharin sodium solution of normal guinea pigs; S3. Obtain the swimming trajectory of guinea pigs with motion sickness, the swimming trajectory of guinea pigs gavaged with half the normal dose of mozavaptan, the swimming trajectory of guinea pigs gavaged with half the normal dose of isalidone, and the swimming trajectory of guinea pigs gavaged with a combination of half the normal dose of mozavaptan and half the normal dose of isalidone, and compare them with the swimming trajectory of normal guinea pigs.